98642-15-0

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 616-29-5 1,3-Diamino-2-hydroxypropane 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 790701-04-1 1,3-di(t-butoxycarbonylamino)-2-(4-nitrophenyl-carbonyloxy)-propane 
• 733010-52-1 1,3-di(tert-butyloxycarbonylamino)-2-[(tetradecylthio)acetyloxy]-propane 
• 98642-16-1 (1,3-bis-2-propyl) p-toluenesulfonate 
• 1122410-51-8 benzoic acid 2-tert-butoxycarbonylamino-1-(tert-butoxycarbonylaminomethyl)ethyl ester 
• 1393477-02-5 [2-({[(benzyloxy)carbonyl]amino}methyl)-1,3-bis({[(tert-butoxy)carbonyl]amino})propan-2-yl]-λ1-oxidanyl 
• 1332761-04-2 [3-tert-butoxycarbonylamino-2-(5-fluoro-2-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester 
• 2387-23-7 1,3-Dicyclohexylurea 
• 213475-68-4 (2-Benzyloxycarbonylamino-3-tert-butoxycarbonylamino-propyl)-carbamic acid tert-butyl ester 
• 566201-39-6 C₆₉H₁₀₂N₁₀O₂₁ 
• 503442-20-4 4-[2-(tert-butoxycarbonylamino)-1-(tert-butoxycarbonylaminomethyl)ethyloxycarbonyl]benzoic acid 
• 149876-86-8 di-tert-butyl (2-aminopropane-1,3-diyl)dicarbamate 
• 870640-36-1 (3-tert-butoxycarbonylamino-2-phenylacetylaminopropyl)carbamic acid tert-butyl ester 
• 518335-42-7 2-(tert-butoxycarbonylamino)-1-(tert-butoxycarbonylaminomethyl)ethyl 4-formylbenzoate 

Relevant academic research and scientific papers

Design, synthesis, and mode of action studies of a mitomycin tetramer inducing double activations with a single probe

We report design, synthesis, and mechanistic studies of a new mitomycin tetramer 9 along with a new mitomycin dimer 10. Mitomycin 9 is a tetramer connected by the disulfide linker 11, and easily undergoes disulfide cleavage to provide two dimeric structures 9r that each contains a single thiol probe for activations. So, tetramer 9 as a precursor of 9r was specifically targeted to undergo double activations with a single probe. A tetramer 9 was synthesized using 1 and key intermediate 11, and a dimer 10 was synthesized from 1 and diamine 12. Activation studies revealed that 9 underwent effective double activations with a single probe by nucleophiles while the reference 10 did not. Evaluations of DNA ISC formations showed that 9 generated substantial levels of DNA ISC by nucleophilic activation while the references 10 and 2 did not. The effectiveness of 9 in activation and formation of DNA ISC per probe was verified by comparing with dimers 5–8 of double activations with two probes. These findings highlighted the role of a single thiol in 9r and demonstrated the intended double activations with a single probe, which marks the first case in mitomycin studies.

A Click Chemistry Approach to Targeted DNA Crosslinking with cis-Platinum(II)-Modified Triplex-Forming Oligonucleotides

Limitations of clinical platinum(II) therapeutics include systemic toxicity and inherent resistance. Modern approaches, therefore, seek new ways to deliver active platinum(II) to discrete nucleic acid targets. In the field of antigene therapy, triplex-forming oligonucleotides (TFOs) have attracted interest for their ability to specifically recognise extended duplex DNA targets. Here, we report a click chemistry based approach that combines alkyne-modified TFOs with azide-bearing cis-platinum(II) complexes—based on cisplatin, oxaliplatin, and carboplatin motifs—to generate a library of PtII-TFO hybrids. These constructs can be assembled modularly and enable directed platinum(II) crosslinking to purine nucleobases on the target sequence under the guidance of the TFO. By covalently incorporating modifications of thiazole orange—a known DNA-intercalating fluorophore—into PtII-TFOs constructs, enhanced target binding and discrimination between target and off-target sequences was achieved.

Rational Design of Covalent Cobaloxime-Covalent Organic Framework Hybrids for Enhanced Photocatalytic Hydrogen Evolution

Covalent organic frameworks (COFs) display a unique combination of chemical tunability, structural diversity, high porosity, nanoscale regularity, and thermal stability. Recent efforts are directed at using such frameworks as tunable scaffolds for chemica

Membrane Phospholipid Analogues as Molecular Rulers to Probe the Position of the Hydrophobic Contact Point of Lysophospholipid Ligands on the Surface of G-Protein-Coupled Receptor during Membrane Approach

When lipid mediators bind to G-protein-coupled receptors (GPCRs), the ligand first enters the lipid bilayer, then diffuses laterally in the cell membrane to make hydrophobic contact with the receptor protein, and finally enters the receptor's binding pock

SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted 3,3'-bis(phenoxymethyl)-1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

Cisplatin probe system and preparation method and application thereof

The invention provides a cisplatin probe system. The cisplatin probe system has a structure shown in a formula I. The cisplatin probe system is a metal probe system capable of rapidly enriching, acquiring and analyzing platinum-bound protein groups from cells, the study of the platinum-bound protein groups is promoted, the mechanism of action of platinum-based anticancer drugs can be understood further, and a theoretical basis for drug improvement is provided.

Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same

The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).

Traceable platinum(II) complexes with alkylene diamine-derived ligands: synthesis, characterization and in vitro studies

Diiodido- (6a/6b) and dichloridoplatinum(II) complexes (7a/7b) with fluorescent ligands 2-[(2-aminoethyl)amino]ethyl-2-(methylamino)benzoate (5a) and 2-amino-1-(aminoethyl)ethyl-2-(methylamino)benzoate (5b) were prepared and characterized by elemental ana

LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME

A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R1 and R2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.

NEW ANTIBACTERIAL PRODUCTS

The invention provides novel antibacterial compounds of formulae IA, IB and IC as defined herein. Optionally, the antibacterial compounds can be bonded to a delivery agent that is capable of bonding to one or more structures on a bacterial cell membrane. The invention also provides the use of such compounds in treating or preventing bacterial infections, and processes for their synthesis.